Corbus Pharmaceuticals still shows promise, with CRB-701 and CRB-601 advancing in clinical trials. Read why CRBP stock is ...

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will participate in a fireside chat and ...

Shares of Corbus Pharmaceuticals Holdings Inc. CRBP rose 1.40% to $18.78 Friday, on what proved to be an all-around great ...

We can readily understand why investors are attracted to unprofitable companies. Indeed, Corbus Pharmaceuticals Holdings ( NASDAQ:CRBP) stock is up 478% in the last year, providing strong gains for ...

Corbus Pharmaceuticals Holdings ( (CRBP) ) has released its Q3 earnings. Here is a breakdown of the information Corbus Pharmaceuticals Holdings ...

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP – Get Free Report) has received an average recommendation of “Buy” from ...

Corbus Pharmaceuticals Holdings Inc. (CRBP) on Thursday reported a loss of $13.8 million in its third quarter. On a per-share basis, the ...

On Wednesday, B.Riley initiated coverage on Corbus Pharmaceuticals (NASDAQ:CRBP) with a Buy rating and a price target of $85.00. The firm's coverage is based on the potential of... NORWOOD, MA ...

Corbus Pharmaceuticals (CRBP) presents new pre-clinical data at Obesity Week 2024 further characterizing CRB-913, its highly peripherally restricted CB1 inverse agonist. The data are being ...

NORWOOD, Mass. (AP) — NORWOOD, Mass. (AP) — Corbus Pharmaceuticals Holdings Inc. (CRBP) on Thursday reported a loss of $13.8 million in its third quarter. On a per-share basis, the Norwood ...